AIP Mutation Identified in a Patient with Acromegaly Caused by Pituitary Somatotroph Adenoma with Neuronal Choristoma

Abstract

Pituitary adenoma with neuronal choristoma (PANCH) is a rare condition that includes ganglion cells and GH-producing tumor that is characterized by sparsely granulated somatotroph cell type. However, the pathophysiology of this condition remains to be elucidated. We report a case of 46-year-old woman with acromegaly caused by PANCH. The patient had a large and invasive macroadenoma that was resistant to preoperative therapy with somatostatin analogue (SSA) and dopamine agonist. Histological examination showed typical diffuse, chromophobe-type adenoma containing ganglion cells, and sparsely granulated somatotroph cell type, which were consistent with PANCH. Genetic analysis showed heterozygous germline missense mutation in the AIP gene that results in Y261X amino acid substitution. The clinical characteristics of acromegaly associated with AIP mutations are reportedly macroadenomas with tumor extension and invasion, lower decreases in GH and IGF-I and less tumor shrinkage with SSA treatment, and sparsely granulated somatotroph cell type, which are comparable with those observed in PANCH. Taken together, the mutation in AIP gene may explain the clinical characteristics and pathogenesis of PANCH.

Key words

AIP - mutation - PANCH - acromegaly - octreotide

• References

• 1 Li JY, Racadot O, Kujas M et al. Immunocytochemistry of four mixed pituitary adenomas and intrasellar gangliocytomas associated with different clinical syndromes: acromegaly, amenorrhea-galactorrhea, Cushing’s disease and isolated tumoral syndrome. Acta Neuropathol 1989; 77: 320-328
• 2 Horvath E, Kovacs K, Scheithauer BW et al. Pituitary adenoma with neuronal choristoma (PANCH): composite lesion or lineage infidelity?. Ultrastruct Pathol Nov-Dec 1994; 18: 565-574
• 3 Sharma MC, Karak AK, Mahapatra AK et al. Pituitary adenoma with neuronal choristoma: a report of two rare cases. Clin Neurol Neurosurg Jun 1999; 101: 128-132
• 4 Towfighi J, Salam MM, McLendon RE et al. Ganglion cell-containing tumors of the pituitary gland. Arch Pathol Lab Med Apr 1996; 120: 369-377
• 5 Puchner MJ, Ludecke DK, Saeger W et al. Gangliocytomas of the sellar region – a review. Exp Clin Endocrinol Diabetes 1995; 103: 129-149
• 6 Geddes JF, Jansen GH, Robinson SF et al. ‘Gangliocytomas’ of the pituitary: a heterogeneous group of lesions with differing histogenesis. Am J Surg Pathol Apr 2000; 24: 607-613
• 7 Saeger W, Puchner MJ, Ludecke DK. Combined sellar gangliocytoma and pituitary adenoma in acromegaly or Cushing’s disease. A report of 3 cases. Virchows Arch 1994; 425: 93-99
• 8 Kontogeorgos G, Mourouti G, Kyrodimou E et al. Ganglion cell containing pituitary adenomas: signs of neuronal differentiation in adenoma cells. Acta Neuropathol Jul 2006; 112: 21-28
• 9 Koutourousiou M, Kontogeorgos G, Wesseling P et al. Collision sellar lesions: experience with eight cases and review of the literature. Pituitary 2010; 13: 8-17
• 10 Asa SL, Scheithauer BW, Bilbao JM et al. A case for hypothalamic acromegaly: a clinicopathological study of six patients with hypothalamic gangliocytomas producing growth hormone-releasing factor. J Clin Endocrinol Metab May 1984; 58: 796-803
• 11 Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature Dec 10-16 1987; 330: 566-568
• 12 Weinstein LS, Shenker A, Gejman PV et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med Dec 12 1991; 325: 1688-1695
• 13 Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest Nov 2009; 119: 3189-3202
• 14 Vierimaa O, Georgitsi M, Lehtonen R et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science May 26 2006; 312: 1228-1230
• 15 Chahal HS, Chapple JP, Frohman LA et al. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol Metab Jul 2010; 21: 419-427
• 16 Leontiou CA, Gueorguiev M, van der Spuy J et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab Jun 2008; 93: 2390-2401
• 17 Daly AF, Tichomirowa MA, Petrossians P et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab Nov 2010; 95: E373-E383
• 18 Cazabat L, Libe R, Perlemoine K et al. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur J Endocrinol Jul 2007; 157: 1-8
• 19 Georgitsi M, De Menis E, Cannavo S et al. Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clin Endocrinol (Oxf) Oct 2008; 69: 621-627
• 20 Trivellin G, Korbonits M. AIP and its interacting partners. J Endocrinol Aug 2011; 210: 137-155
• 21 Yoneda A, Sano T, Yamada S et al. Pituitary adenomas that show a faint GH-immunoreactivity but lack fibrous body: Pit-1 adenoma with endocrinologically low activity. Endocr Pathol Mar 2010; 21: 40-47
• 22 Ezzat S, Kontogeorgos G, Redelmeier DA et al. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol Dec 1995; 133: 686-690
• 23 Bhayana S, Booth GL, Asa SL et al. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab Nov 2005; 90: 6290-6295
• 24 Guaraldi F, Salvatori R. Familial isolated pituitary adenomas: from genetics to therapy. Clin Transl Sci Feb 2011; 4: 55-62
• 25 Petrulis JR, Perdew GH. The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chem Biol Interact Sep 20 2002; 141: 25-40
• 26 Tichomirowa MA, Barlier A, Daly AF et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol Oct 2011; 165: 509-515
• 27 Jaffrain-Rea ML, Angelini M, Gargano D et al. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr Relat Cancer Sep 2009; 16: 1029-1043
• 28 Dougherty EJ, Pollenz RS. Analysis of Ah receptor-ARNT and Ah receptor-ARNT2 complexes in vitro and in cell culture. Toxicol Sci May 2008; 103: 191-206
• 29 Raitila A, Lehtonen HJ, Arola J et al. Mice with inactivation of aryl hydrocarbon receptor-interacting protein (Aip) display complete penetrance of pituitary adenomas with aberrant ARNT expression. Am J Pathol Oct 2010; 177 () 1969-1976
• 30 Hosoya T, Oda Y, Takahashi S et al. Defective development of secretory neurones in the hypothalamus of Arnt2-knockout mice. Genes Cells Apr 2001; 6: 361-374